Pure Global AI
NCT06415266Not yet recruiting

Assessment the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request

Multicentric Randomized Study eValuating the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request
Institut du Cancer de Montpellier - Val d'AurelleClinicalTrials.govother
Verified
Study focus
Disease/Condition
Breast Cancer
Drug/Device/Intervention
Quality of life questionnaire (QLQ)
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Location
Saint-Herblain,Vandœuvre-lès-Nancy,Lyon,Montpellier,Nice,Nîmes,Paris,Toulouse,Villejuif, France
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2028
Enrollment
264 participants
Primary outcome

Comparison of the quality of sexual life of patients in the intervention arm and patients in the control arm

Summary

The study compares the quality of sexual life of breast cancer patients under two types of
 oncoSexology supportive care : personalized supportive care versus on-request. The aim is to
 improve the quality of sexual life of these patients.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedMalignant neoplasm: Breast, unspecifiedOther carcinoma in situ of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06415266
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06415266 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle and is currently Not yet recruiting. The study focuses on Breast Cancer. Target enrollment is 264 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.